Roche's Breast Cancer Combo Therapy Offers Tiny Benefit In Large Drug Trial - And It's A Pricey Drug

Roche's new combination therapy achieved modest positive results compared with the company's standard Herceptin treatment. The combo therapy targets an aggressive form of breast cancer called HER2-positive, and involves adding Perjeta to the existent Herceptin plus chemo treatment.